| Initiation of antiretroviral therapy in early asymptomatic HIV infection Insight Start Study Group New England Journal of Medicine 373 (9), 795-807, 2015 | 3293 | 2015 |
| Combination antiretroviral therapy and the risk of myocardial infarction Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group New England Journal of Medicine 349 (21), 1993-2003, 2003 | 2137 | 2003 |
| Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: A: D study: a multi-cohort collaboration D: A: D Study Group The Lancet 371 (9622), 1417-1426, 2008 | 1189 | 2008 |
| Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): a multicohort collaboration CJ Smith, L Ryom, R Weber, P Morlat, C Pradier, P Reiss, JD Kowalska, ... The Lancet 384 (9939), 241-248, 2014 | 1174 | 2014 |
| Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ... New England Journal of Medicine 369 (19), 1807-1818, 2013 | 1073 | 2013 |
| Maraviroc for previously treated patients with R5 HIV-1 infection RM Gulick, J Lalezari, J Goodrich, N Clumeck, E DeJesus, A Horban, ... New England Journal of Medicine 359 (14), 1429-1441, 2008 | 941 | 2008 |
| Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 913 | 2008 |
| Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti, C Orkin, M Bloch, ... The Lancet 381 (9868), 735-743, 2013 | 681 | 2013 |
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects M J Buzón, M Massanella, JM Llibre, A Esteve, V Dahl, MC Puertas, ... Nature medicine 16 (4), 460-465, 2010 | 664 | 2010 |
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 616 | 2008 |
| Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, ... Aids 24 (11), 1667-1678, 2010 | 539 | 2010 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 531 | 2021 |
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind … F Raffi, H Jaeger, E Quiros-Roldan, H Albrecht, E Belonosova, JM Gatell, ... The Lancet infectious diseases 13 (11), 927-935, 2013 | 522 | 2013 |
| Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study N Friis-Møller, R Thiebaut, P Reiss, R Weber, A D'Arminio Monforte, ... European journal of cardiovascular prevention & rehabilitation 17 (5), 491-501, 2010 | 475 | 2010 |
| Smallpox: the triumph over the most terrible of the ministers of death N Barquet, P Domingo Annals of internal medicine 127 (8_Part_1), 635-642, 1997 | 449 | 1997 |
| Clinical utility of HIV-1 genotyping and expert advice: the Havana trial C Tural, L Ruiz, C Holtzer, J Schapiro, P Viciana, J González, P Domingo, ... Aids 16 (2), 209-218, 2002 | 437 | 2002 |
| Interleukin-2 therapy in patients with HIV infection INSIGHT–ESPRIT Study Group and SILCAAT Scientific Committee New England Journal of Medicine 361 (16), 1548-1559, 2009 | 435 | 2009 |
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection G Fätkenheuer, M Nelson, A Lazzarin, I Konourina, AIM Hoepelman, ... New England Journal of Medicine 359 (14), 1442-1455, 2008 | 430 | 2008 |
| Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: a cohort study J Del Amo, R Polo, S Moreno, A Díaz, E Martínez, JR Arribas, I Jarrín, ... Annals of internal medicine 173 (7), 536-541, 2020 | 411 | 2020 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection E Martínez, JA Arnaiz, D Podzamczer, D Dalmau, E Ribera, P Domingo, ... New England Journal of Medicine 349 (11), 1036-1046, 2003 | 388 | 2003 |
